EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Bought by Wellington Management Group LLP

Wellington Management Group LLP grew its stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 59.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 171,764 shares of the company’s stock after buying an additional 64,008 shares during the period. Wellington Management Group LLP’s holdings in EyePoint Pharmaceuticals were worth $1,372,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of EYPT. Greenwich Wealth Management LLC increased its position in EyePoint Pharmaceuticals by 8.3% during the third quarter. Greenwich Wealth Management LLC now owns 11,700 shares of the company’s stock worth $93,000 after buying an additional 900 shares during the period. Arizona State Retirement System boosted its holdings in shares of EyePoint Pharmaceuticals by 9.7% in the second quarter. Arizona State Retirement System now owns 13,251 shares of the company’s stock valued at $115,000 after acquiring an additional 1,171 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of EyePoint Pharmaceuticals by 68.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company’s stock worth $82,000 after acquiring an additional 4,172 shares during the last quarter. Fiera Capital Corp increased its holdings in shares of EyePoint Pharmaceuticals by 0.9% in the 2nd quarter. Fiera Capital Corp now owns 677,038 shares of the company’s stock valued at $5,890,000 after acquiring an additional 5,920 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in EyePoint Pharmaceuticals by 271.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,888 shares of the company’s stock valued at $95,000 after purchasing an additional 7,953 shares during the last quarter. 99.41% of the stock is owned by hedge funds and other institutional investors.

EyePoint Pharmaceuticals Stock Performance

NASDAQ:EYPT opened at $7.12 on Friday. The stock has a market capitalization of $485.95 million, a price-to-earnings ratio of -3.56 and a beta of 1.45. EyePoint Pharmaceuticals, Inc. has a 1 year low of $7.04 and a 1 year high of $30.99. The stock has a fifty day moving average price of $9.74 and a two-hundred day moving average price of $9.12.

Wall Street Analysts Forecast Growth

A number of research firms have commented on EYPT. Chardan Capital lifted their price objective on shares of EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the company a “buy” rating in a research note on Friday, November 8th. HC Wainwright restated a “buy” rating and issued a $22.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday, December 5th. Scotiabank began coverage on EyePoint Pharmaceuticals in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $18.00 price objective for the company. StockNews.com upgraded EyePoint Pharmaceuticals to a “sell” rating in a research note on Saturday, September 21st. Finally, Jefferies Financial Group began coverage on EyePoint Pharmaceuticals in a report on Wednesday, August 28th. They set a “buy” rating and a $15.00 price target for the company. One analyst has rated the stock with a sell rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, EyePoint Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.71.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.